SPX4,076.57-3.54 -0.09%
DIA344.41-1.74 -0.50%
IXIC11,482.45+14.45 0.13%

HC Wainwright & Co. Downgrades Neoleukin Therapeutics to Neutral

Benzinga · 11/16/2022 06:19
HC Wainwright & Co. analyst Robert Burns downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.